Being tested
Walking (potassium-channel blockade): improve symptoms or function in MS (type not specified)
Trial timeline
Trial start year. Dot size reflects participants where reported. Only trials that count towards the status are shown.
MS (type not specified) · Walking (potassium-channel blockade)
Trials are running now and no controlled trial has a readable result yet.
- Trials
- 19
- Running now
- 2
- Controlled phase 2/3 trials
- 10
- People in controlled trials
- 1551
Deciding trials (phase 3): 2 met, 1 did not.
Other linked trials: 16
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
- Prolonged-release oral Fampridine in Multiple Sclerosis: effects on clinical, neurophysiological and quantified gait analysis parameters.decides the statusNo result found
Phase 3 · 2012 · Placebo-controlled · MSFT-2012-005076-34
- Study of Fampridine-ER Tablets in Patients With Multiple Sclerosisdecides the statusMissed main goal
Phase 3 · 2011 · Placebo-controlled · MSFT-NCT01328379
Phase 3 · 2007 · Placebo-controlled · MSFT-NCT00483652
The proportion of TWRs was higher in the dalfampridine group (51/119 or 42.9%) compared to the placebo group (11/118 or 9.3%, p < 0.0001).
Read by software from the paper's abstractPhase 3 · 2005 · Placebo-controlled · MSFT-NCT00127530
The proportion of timed walk responders was higher in the fampridine group (78/224 or 35%) than in the placebo group (6/72 or 8%; p<0.0001).
Read by software from the paper's abstractPhase 2/3 · 2011 · Placebo-controlled · MSFT-NCT02006160
Our primary outcome, performance on the Symbol Digit Modalities Test, did not improve.
Read by software from the paper's abstract- Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosisdecides the statusNo result found
Phase 2/3 · 2011 · Placebo-controlled · MSFT-NCT05859802
Other linked trials: 16
These linked trials do not set the status.
- Fampridine Study in Activities of Daily LivingNo result found
Phase 4 · 2015 · Not randomised
- Efficacy of Dalfampridine on Upper Extremity Function in Patients With MSResult in a paper, not read yet
Phase 4 · 2014 · Placebo-controlled
- FAMPISEPResult in a paper, not read yet
Phase 4 · 2014 · Not randomised
- Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS PatientsResult in a paper, not read yet
Phase 4 · 2013 · Placebo-controlled
- improvement of cognitive performance after administration of fampridina in patients with multiple sclerosisResult in a paper, not read yet
Phase 4 · 2013 · Placebo-controlled
- A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple SclerosisMissed main goal
Phase 4 · 2010 · Placebo-controlled
- AmpPTOngoing
Phase 3 · 2024 · Not randomised
Phase 3 · 2005 · Not randomised
Phase 2 · 2014 · Placebo-controlled
Phase 2 · 2012 · Placebo-controlled
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Trials: 21 → 19
- 2026-10-28Trials: 22 → 21
- 2026-10-27First listed as Being tested
Related hypotheses
- Walking (potassium-channel blockade): improve symptoms or function in NMOSD
- Walking (potassium-channel blockade): improve symptoms or function in optic neuritis
- Walking (potassium-channel blockade): improve symptoms or function in primary progressive MS
- Walking (potassium-channel blockade): improve symptoms or function in relapsing MS
- Walking (potassium-channel blockade): improve symptoms or function in relapsing and progressive MS
- Walking (potassium-channel blockade): improve symptoms or function in secondary progressive MS
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error